-
Product Insights
NewNet Present Value Model: Sanofi’s INBRX-101
Empower your strategies with our Net Present Value Model: Sanofi's INBRX-101 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence. emphysema. The therapeutic candidate comprises of alpha-1 antitrypsin (AAT)-Fc fusion proteins and developed based...
-
Product Insights
NewNet Present Value Model: Inhibrx Inc’s INBRX-101
Empower your strategies with our Net Present Value Model: Inhibrx Inc's INBRX-101 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence. emphysema. The therapeutic candidate comprises of alpha-1 antitrypsin (AAT)-Fc fusion proteins and developed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GIGA-564 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GIGA-564 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GIGA-564 in Solid Tumor Drug Details: GIGA-564 is under development for...
-
Product Insights
NewAbcodia Ltd Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Abcodia Ltd Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Abcodia Ltd (Abcodia) is a clinical stage company that offers commercial development of novel, scientifically validated tests for the early detection of cancer. The company offers Roca Test, a blood test for early ovarian cancer detection. It validates and discovers biomarkers for early diagnosis and screening of cancer. Abcodia develops products for the detection of colorectal cancer, pancreatic cancer and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CUSP-06 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CUSP-06 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CUSP-06 in Ovarian Cancer Drug Details: CUSP-06 (AMT-707) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CUSP-06 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CUSP-06 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CUSP-06 in Solid Tumor Drug Details: CUSP-06 (AMT-707) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-211 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-211 in Esophageal Cancer Drug Details: BNT-211 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-211 in Testicular Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Testicular Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-211 in Testicular Cancer Drug Details: BNT-211 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-211 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-211 in Ovarian Cancer Drug Details: BNT-211 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-211 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-211 in Gastric Cancer Drug Details: BNT-211 is under development for...